Increased neutrophil-lymphocyte ratio in patients with COPD: case-control study




Research Article

American Journal of BioMedicine
Volume 11, Issue 3, 2023, Pages 144-157 

10.18081/2333-5106/2023.11/144

Ahad Jamel Abd AL-Hussein1, Ghadeer Mohammed Abad Alruda1, Nasser Ghaly Yousif2

Received 11 March 2023; Revised 22 July 2023; Accepted 11 August 2023; Published 28 August 2023


 

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the major causes of chronic morbidity and mortality and one of the major public health problems worldwide that affects millions of people all over the world. It is characterized by persistent airflow obstruction associated with enhanced inflammation in the airways and the lungs in response to noxious particles or gases. The main objective of this study is to investigate the neutrophil-lymphocyte ratio in patients with COPD as a case-control study. Between November 01, 2022, and February 28, 2023, patients were admitted to Al Hussain Teaching Hospital in Al Muthanna Governorate, Department of Medicine. The study included 51 patients with an approved diagnosis of COPD the mean age was 51.5 years, and 51 patients as control with other diseases mean age was 51.3 years). The subjects in all groups were 32 male and 19 female. Complete blood count (CBC) was measured from blood samples taken from patients. In the present study 51 COPD cases and 51 controls. No significant difference was observed between COPD cases and controls regarding age (p = 0.092); the average age of COPD cases was 51.5 years. No significant differences were observed between COPD cases and controls regarding gender (p = 0.085). At baseline, 21.0%, 40.3%, 25.7%, and 13% were diagnosed as COPD grade 1, 2, 3, and 4, respectively based on the (GOLD) classification. Baseline NLR significantly increased with the severity of COPD grade (1.3 vs. 2.7 vs. 2.2 vs. 2.9), p = 0.002). The cutoff for neutrophil-to-lymphocyte ratio, CRP, WBC, and ESR were 3.28, 2.32, 1.22, and 4.21 respectively. It has 85% sensitivity for detection of COPD exacerbation. and 89% specificity (AUC 0.798, p = 0.001). In conclusion, Blood NLR is a simple, inexpensive, widely available index that has been intensively evaluated in recent years in several clinical applications and in various diseases, including COPD.

Keywords: COPD; Neutrophil-lymphocyte; Complete blood count  

Copyright © 2023 Yousif NG et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cited by other articlesReferencesStatistics
The citation data is computed by the following citation measuring services:Google Scholar
Cited by CrossRef (0)
Cited by Scopus ()

1. Kumar P, Law S, Sriram KB. Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis 2017; 9:1509-16.
https://doi.org/10.21037/jtd.2017.05.77
2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691-706.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
https://doi.org/10.1016/S0140-6736(12)61728-0
4. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160(5 Pt 2):S49-52.
https://doi.org/10.1164/ajrccm.160.supplement_1.13
5. Zhao QT, Yuan Z, Zhang H, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3720 patients. Int J Cancer 2016; 139:164-70.
https://doi.org/10.1002/ijc.30060
6. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005 Sep;26(3):420-8.
https://doi.org/10.1183/09031936.05.00136304
7. Moore WC, Hastie AT, Li X. Sputum neutrophils are associated with more severe asthma phenotypes using cluster analysis. Journal of Allergy and Clinical Immunology 2014; 133:1557-1563.
https://doi.org/10.1016/j.jaci.2013.10.011
8. Bloemen K, Van Den Heuvel R, Govarts E. A new approach to study exhaled proteins as potential biomarkers for asthma. Clinical and Experimental Allergy 2011; 41: 346-356.
https://doi.org/10.1111/j.1365-2222.2010.03638.x
9. Imtiaz F, Shafique K, Mirza SS. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. International Archives of Medicine 2012; 5: 2.
https://doi.org/10.1186/1755-7682-5-2
10. Zhang XY, Simpson JL, Powell H. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clinical and Experimental Allergy 2014; 44: 1137-1145.
https://doi.org/10.1111/cea.12345
11. Uthamalingam S, Patvardhan EA, Subramanian S. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011; 107(3):433-438.
https://doi.org/10.1016/j.amjcard.2010.09.039
12. Azab B, Bhatt VR, Phookan J. Usefulness of the neutrophil-to lymphocyte ratio in predicting short-and long term mortality in breast cancer patients. Ann Surg Oncol 2012; 19(1):217-224.
https://doi.org/10.1245/s10434-011-1814-0
13. de Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink J,van der Poll T, Wever PC. Lymphocytopenia and neutrophillymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 2010; 14(5): R192.
https://doi.org/10.1186/cc9309
14. Alkhouri N, Morris-Stiff G, Campbell C. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2012; 32(2):297-302.
https://doi.org/10.1111/j.1478-3231.2011.02639.x
15. Spark JI, Sarveswaran J, Blest N, Charalabidis P, Asthana S. An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia. J Vasc Surg 2010; 52(3):632-636.
https://doi.org/10.1016/j.jvs.2010.03.067
16. Ouellet G, Malhotra R, Penne EL, Usvya L, Levin NW, Kotanko P. Neutrophil-lymphocyte ratio as a novel predictor of survival in chronic hemodialysis patients. Clin Nephrol 2016; 85(4):191-198.
https://doi.org/10.5414/CN108745
17. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386 (9998): 1086-1096.
https://doi.org/10.1016/S0140-6736(15)00157-9
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011; 61 (2): 69-90.
https://doi.org/10.3322/caac.20107
19. Mattos WL, Signori LG, Borges FK, Bergamin JA, Machado V. Accuracy of clinical examination findings in the diagnosis of COPD. J Bras Pneumol 2009; 35(5):404-8.
https://doi.org/10.1590/S1806-37132009000500003
20. Changizi M, Rio K. Harnessing color vision for visual oximetry in central cyanosis. Med Hypotheses 2010;74(1):87-91.
https://doi.org/10.1016/j.mehy.2009.07.045
21. Qaseem A, Wilt TJ, Weinberger SE, et al. American College of Physicians. American College of Chest Physicians. American Thoracic Society. European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3):179-91.
https://doi.org/10.7326/0003-4819-155-3-201108020-00008
22. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379(9823):1341-51.
https://doi.org/10.1016/S0140-6736(11)60968-9
23. FLETCHER CM, ELMES PC, FAIRBAIRN AS, WOOD CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2(5147):257-66.
https://doi.org/10.1136/bmj.2.5147.257
24. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-7.
https://doi.org/10.1164/ajrccm.166.1.at1102
25. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s - Diagnosis and management (2018, updated 2019). (Accessed on March 23, 2020).
26. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. (Accessed on December 13, 2022).
27. Kochanek KD, Murphy SL, Xu J, Arias E. Mortality in the United States, 2016 NCHS Data Brief 2017 pdf (Accessed on July 16, 2019)
28. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22(4):672-688.
https://doi.org/10.1183/09031936.03.00040703
29. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364(9435):709-721.
https://doi.org/10.1016/S0140-6736(04)16900-6
30. Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49:1600791.
https://doi.org/10.1183/13993003.00791-2016
31. Leuppi JD, Schuetz P, Bingisser R et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309:2223-31.
https://doi.org/10.1001/jama.2013.5023
32. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2019 report.
33. American Lung Association (ALA). (2017). PDF GOLD Pocket Guide. Retrieved February 20, 2018 from goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf.
34. COPD. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/copd. Accessed May 28, 2019.
35. Labarca G, et al. Bronchoscopic lung volume reduction with endobronchial Zephyr Valves for severe emphysema: A systematic review and meta-analysis. Respiration. 2019.
https://doi.org/10.1159/000499508
36. Singh D, Agusti A, Anzueto A, Barnes PJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019; 53(5).
https://doi.org/10.1183/13993003.00164-2019
37. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2005; 60(1):23-29.
https://doi.org/10.1111/j.1398-9995.2005.00632.x
38. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24(1):122-128.
https://doi.org/10.1183/09031936.04.00077803
39. Harrison's Principles of Internal Medicine. 20th ed. McGraw Hill; 2018. Ralston, S. H., Penman, I. D., Strachan, M. W. J., & Hobson, R. (Eds.). (2018). Davidson's principles and practice of medicine (23rd ed.).
40. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):2095-2128.
https://doi.org/10.1016/S0140-6736(12)61728-0
41. Molfino NA. Genetic predisposition to accelerated decline of lung function in COPD. Int J Chron Obstruct Pulmon Dis 2007; 2(2):117.
42. Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10:2207-2217.
https://doi.org/10.2147/COPD.S91694
43. Moons P, Van Deyk K, Budts W, De Geest S. Caliber of quality-of-life assessments in congenital heart disease: a plea for more conceptual and methodological rigor. Arch Pediatr Adolesc Med 2004;158(11):1062-1069.
https://doi.org/10.1001/archpedi.158.11.1062
44. Garrido PC, de Miguel Díez J, Gutiérrez JR, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006;4(1):31.
https://doi.org/10.1186/1477-7525-4-31
45. Garrido PC, de Miguel Díez J, Gutiérrez JR, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006;4(1):31.
https://doi.org/10.1186/1477-7525-4-31
46. Dignani L, Toccaceli A, Lucertini C, Petrucci C, Lancia L. Sleep and quality of life in people with COPD: a descriptive-correlational study. Clin Nurs Res 2016;25(4):432-447.
https://doi.org/10.1177/1054773815588515
47. Moro JMR-G, Izquierdo JL, Antón E, de Lucas P, Martín A, Group MS. Health-related quality of life in outpatient women with COPD in daily practice: the MUVICE Spanish study. Respir Med 2009;103(9):1303-1312.
https://doi.org/10.1016/j.rmed.2009.04.002


Volume 11, Issue 3
August to October 2023
Pages 144-157

 

File and statistics

 

How to cite

APA
Chandra, S., and Vijayakumar, V. (2023). Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors. American Journal of BioMedicine, 11(1), 10-21.doi: 10.18081/2333-5106/2023.11/10
MLA
Sambit Chandra; Sujeet D. Vijayakumar. “Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors”. American Journal of BioMedicine, 11, 1, 2023, 10-21. doi: 10.18081/2333-5106/2023.11/10
HARVARD
Chandra, S., Vijayakumar, V. (2023). Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors. American Journal of BioMedicine, 11(1), PP. 10-21.doi: 10.18081/2333-5106/2023.11/10
VANCOUVER
Abd AL-Hussein AJ, Abad Alruda GM, Yousif NG. Increased neutrophil-lymphocyte ratio in patients with COPD: case-control study . American Journal of BioMedicine 2023; 11(3):144-157

Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles published in American Journal of BioMedicine  are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.